Work

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1166

Authors: R.J. Sullivan, M. Lu, S. Koppolu, J.S. Weber, M.S. Carlino, M.A. Khattak, G. Ansstas, M.H. Taylor, M. Mckean, G.V. Long, M.B. Faries, J.J. Luke, V. Sehgal, A. Rao, H. Mao, J. Guo, M. Brown, R. Meehan, I. Feldman, L. Srinivasan

Institutions: Massachusetts General Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Westmead Hospital, Melanoma Institute Australia, Edith Cowan University, Hollywood Private Hospital, Washington University in St. Louis, Sarah Cannon, The University of Sydney, Royal North Shore Hospital, Angeles Clinic and Research Institute, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402561140

FWCI:

Cites:

Cited by:

Related to: 10